CytomX Therapeutics (NASDAQ:CTMX) Given New $16.00 Price Target at Barclays

CytomX Therapeutics (NASDAQ:CTMX) had its price objective boosted by analysts at Barclays from $10.00 to $16.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s target price indicates a potential upside of 229.49% from the stock’s current price.

Several other analysts also recently commented on CTMX. Guggenheim boosted their target price on CytomX Therapeutics from $10.00 to $15.00 and gave the stock a “buy” rating in a research note on Wednesday. Cantor Fitzgerald lifted their price target on CytomX Therapeutics from $6.00 to $10.00 and gave the stock an “overweight” rating in a report on Wednesday, February 4th. JPMorgan Chase & Co. upgraded CytomX Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $7.00 to $12.00 in a research note on Monday. HC Wainwright raised their target price on CytomX Therapeutics from $10.00 to $17.00 and gave the company a “buy” rating in a research report on Monday. Finally, Piper Sandler boosted their price target on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, January 20th. Nine analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $13.22.

CytomX Therapeutics Stock Performance

Shares of NASDAQ:CTMX traded up $0.46 during midday trading on Thursday, hitting $4.86. 4,191,836 shares of the stock were exchanged, compared to its average volume of 6,398,991. The business’s 50-day moving average price is $5.27 and its 200 day moving average price is $4.10. CytomX Therapeutics has a 12 month low of $0.40 and a 12 month high of $8.21. The stock has a market capitalization of $826.44 million, a price-to-earnings ratio of -121.63 and a beta of 2.44.

CytomX Therapeutics (NASDAQ:CTMX) last posted its quarterly earnings data on Monday, March 16th. The biotechnology company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The firm had revenue of $0.66 million during the quarter, compared to the consensus estimate of $7.33 million. CytomX Therapeutics had a negative net margin of 22.79% and a negative return on equity of 19.77%. As a group, sell-side analysts expect that CytomX Therapeutics will post -0.05 EPS for the current year.

Institutional Trading of CytomX Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Squarepoint Ops LLC lifted its stake in shares of CytomX Therapeutics by 4.5% in the 4th quarter. Squarepoint Ops LLC now owns 49,897 shares of the biotechnology company’s stock valued at $213,000 after acquiring an additional 2,169 shares during the last quarter. Wells Fargo & Company MN increased its stake in CytomX Therapeutics by 83.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,605 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,000 shares during the period. Velan Capital Investment Management LP lifted its position in CytomX Therapeutics by 6.7% in the third quarter. Velan Capital Investment Management LP now owns 80,000 shares of the biotechnology company’s stock valued at $255,000 after purchasing an additional 5,000 shares during the last quarter. Farther Finance Advisors LLC bought a new stake in CytomX Therapeutics in the third quarter valued at approximately $25,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of CytomX Therapeutics during the fourth quarter valued at approximately $35,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

Key CytomX Therapeutics News

Here are the key news stories impacting CytomX Therapeutics this week:

• Positive Sentiment: Analyst bullishness: Guggenheim raised its price target from $10 to $15 and maintains a Buy rating, signaling strong upside potential if clinical progress continues. Benzinga: Guggenheim raises PT
• Positive Sentiment: More analyst support: Wedbush lifted its price target to $11 and JPMorgan upgraded the stock — these endorsements can buoy sentiment and buying interest. Wedbush Raises CytomX Price Target to $11
• Positive Sentiment: Clinical momentum: CTMX previously rallied on strong Phase I Varseta‑M colorectal cancer data (higher response and disease control), an important fundamental catalyst for a clinical‑stage biotech. Zacks: CTMX Stock Rallies on Strong Phase I Data
• Neutral Sentiment: HC Wainwright reiterated a Buy and high $17 target but cut near‑term EPS estimates across 2026 quarters and pushed FY2026/FY2027 loss projections wider — supportive on target but the estimate cuts add uncertainty. MarketBeat: HC Wainwright estimates update
• Negative Sentiment: Earnings miss: CTMX reported quarterly results that disappointed consensus (EPS and revenue misses), a direct trigger for intraday selling and reduced near‑term confidence. CytomX Shares Down on Disappointing Earnings
• Negative Sentiment: Dilution risk: CytomX priced a $250M offering (≈46M shares at $5.30 plus pre‑funded warrants), which increases share supply and can pressure the stock despite providing cash to fund development. Closing expected March 19. GlobeNewswire: CytomX Announces Pricing of $250M Offering

About CytomX Therapeutics

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.